A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer.
Twenty-three evaluable patients with refractory epithelial ovarian cancer were treated with bisantrene (CL216,942). The drug was given as a single-dose injection every 3 weeks. One patient (4%) showed a partial response. The compound thus has limited activity against this malignancy.